Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SN2310 Injectable Emulsion · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | SN2310 Injectable Emulsion |
| Name | Type | Description |
|---|---|---|
| SN2310 Injectable Emulsion | DRUG | Escalating doses given IV every three weeks |
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of solid tumor with disease progression despite standard therapy and/or for which no other solid therapeutic option exists * ANC \> 1,500 cell/mm3, platelets \> 100,000/mm3 and Hgb \> 9 g/dl * At least one unidimensionally me...
SN2310 Injectable Emulsion is an investigational small molecule being studied for the treatment of breast neoplasms, or breast cancer. It was evaluated in patients with advanced solid tumors, including breast, colorectal, pancreatic, pelvic, and lung neoplasms, in a Phase 1 clinical trial.
SN2310 Injectable Emulsion is a small molecule, but its specific molecular target has not been disclosed. The drug was studied in a Phase 1 dose escalation trial for advanced solid tumors, including breast cancer, but the mechanism of action is not publicly detailed.
SN2310 Injectable Emulsion is being developed by Achieve Life Sciences, Inc., a company traded on the NASDAQ under the ticker symbol ACHV. The company conducted a Phase 1 clinical trial of the drug in patients with advanced solid tumors.
SN2310 Injectable Emulsion is in Phase 1 clinical development. It has completed a Phase 1 dose escalation study, and the drug remains investigational, meaning it has not been approved by the FDA for any use.
SN2310 Injectable Emulsion has one completed clinical trial, NCT00385177, titled 'Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors.' The study enrolled 61 participants in the United States and was not randomized or blinded.
SN2310 Injectable Emulsion is not known to have any alternative names. It is a distinct investigational drug developed by Achieve Life Sciences, Inc., and no other names for this asset have been reported.